2022-502367-37-00CompletedPhase 1/2
A phase I study of [177Lu]Lu-FF58 in patients with advanced solid tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Dec 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 55 (actual)
- First submitted
- 28 Apr 2023
- Start date
- 29 Nov 2024
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Glioblastoma, Pancreatic cancer
- EU CT number
- 2022-502367-37-00
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 55
- 7 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Completed |
| Institut Catala D'oncologia | L'Hospitalet de Llobregat | Spain | Completed |
| Hospital Universitario Ramón y Cajal | Madrid | Spain | Completed |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Completed |
| Fondazione IRCCS - Istituto Nazionale dei Tumori | Milan | Italy | Completed |
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia | Italy | Completed |
| Stichting Radboud University Medical Center | Nijmegen | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.